People In Brief
This article was originally published in The Gray Sheet
CMS payment group: Jeffrey B. Rich, M.D., will be the new director of CMS' Center for Medicare Management starting Feb. 18. CMM is charged with establishing and overseeing the agency's payment policies and is primarily responsible for implementing ongoing reforms including durable medical equipment competitive bidding and pay-for-performance. Rich is a practicing cardiothoracic surgeon and director-at-large for the Society of Thoracic Surgeons. He has been involved in pay-for-performance initiatives through his work with the National Quality Forum, the Hospital Quality Alliance and the AQA (formerly known as the Ambulatory Care Quality Alliance). CMM has not had a permanent director since Herb Kuhn moved up in ranks to deputy administrator of CMS in late 2006 (1"The Gray Sheet" March 5, 2007, p. 7). Current CMM Acting Director Liz Richter will become the group's permanent deputy
You may also be interested in...
Biomet names CEO: Former Abbott exec Jeffrey Binder succeeds interim CEO Daniel Hann in the top spot at Biomet on Feb. 26. Hann, who will stay with Biomet as executive VP of administration and a member of the board, was named acting CEO in March 2006 when co-founder Dane Miller abruptly resigned (1"The Gray Sheet" April 3, 2006, In Brief). Binder takes over shortly after Biomet agreed to be acquired by an investor consortium for $10.9 billion, or $44 a share (2"The Gray Sheet" Jan. 2007, p. 6). The 15-year orthopedics industry veteran is no stranger to transitioning leadership. Binder supervised the integration of DePuy Orthopedics into Johnson & Johnson in 1998 and served as president of DePuy's joint reconstruction and trauma group until 2000, when he became CEO of Spinal Concepts. That firm was acquired by Abbott in 2003 (3"The Gray Sheet" June 9, 2003, p. 25). Binder led Abbott Spine until Jan. 2006, when he was named VP diagnostic operations. Abbott recently sold its core in vitro diagnostics unit to GE for $8.13 billion (4"The Gray Sheet" Jan. 22, 2007, p. 3)...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.